P2RX7
ENSG00000089041
Target class
Ion channel
Chromosome
12
Approved drugs
0
Clinical candidates (approved and in development)
4
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- No
- Target name
- P2RX7
- Gene name
- Purinergic receptor P2X 7
- Gene symbol
- P2RX7
- Protein name
- P2X purinoceptor 7 (P2X7) (ATP receptor) (P2Z receptor) (Purinergic receptor)
- P2X7
- MGC20089
- Gene biotype
- Protein coding
- Gene family
- Purinergic receptors P2X
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 48
- Highest tissue expression
- 29.07
- Tissue specificity (Gini)
- 0.455
- Tissue specificity (tau)
- 0.78
- KEGG gene identifiers
- hsa:5027
- Protein interaction confidence
- 0.852857
- Protein interaction partners
- 21
- R-HSA-139853
- R-HSA-418346
- R-HSA-844456
- R-HSA-9660826
- R-HSA-9856532
- End position
- 121188032
- Start position
- 121132819
- Chromosome
- 12
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein .
- PubMed 12107182
- PubMed 23303206
- PubMed 28326637
- Tissue specificity (tau)
- 0.780186
- Expression inequality (Gini)
- 0.455151
Expression in transcripts per million
- Brain - Spinal cord (cervical c-1)
- 29.07
- Skin - Sun Exposed (Lower leg)
- 19.19
- Cervix - Ectocervix
- 16.41
- Skin - Not Sun Exposed (Suprapubic)
- 16.33
- Nerve - Tibial
- 16.25
Expression in transcripts per million
- Brain - Spinal cord (cervical c-1)29.07
- Skin - Sun Exposed (Lower leg)19.19
- Cervix - Ectocervix16.41
- Skin - Not Sun Exposed (Suprapubic)16.33
- Nerve - Tibial16.25
- Brain - Substantia nigra15.83
- Brain - Cerebellum13.76
- Brain - Hippocampus13.58
- Brain - Cortex13.56
- Ovary13.01
- Brain - Cerebellar Hemisphere12.34
- Lung11.39
- Brain - Frontal Cortex (BA9)10.98
- Cervix - Endocervix9.91
- Brain - Amygdala9.51
- Brain - Putamen (basal ganglia)8.5
- Vagina8.5
- Spleen8.36
- Brain - Hypothalamus8.23
- Brain - Caudate (basal ganglia)7.88
- Uterus7.34
- Brain - Anterior cingulate cortex (BA24)7.23
- Colon - Sigmoid6.47
- Cells - EBV-transformed lymphocytes5.73
- Fallopian Tube5.38
And 29 more, listed on the interactive page.
- GO:0010524
- GO:0010628
- GO:0017121
- GO:0019722
- GO:0032060
- GO:0032731
- GO:0033198
- GO:0034767
- GO:0035590
- GO:0045794
- GO:0045821
- GO:0046931
- GO:0051899
- GO:0070207
- GO:0071318
- GO:1904172
- GO:0005886
- GO:0016020
- GO:0001614
- GO:0004931
- GO:0005267
- GO:0005272
- GO:0005515
- GO:0005524
increased urinary sodium excretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased urinary sodium excretion
- nervous system
- renal
- immune
PubMed 28216264increased urine excretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased urine excretion
- nervous system
- renal
- immune
PubMed 28216264decreased convulsions
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased convulsions
- nervous system
- renal
- immune
PubMed 28216264decreased inflammation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased inflammation
- nervous system
- renal
- immune
PubMed 28216264hemolysis
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: hemolysis
- nervous system
- renal
- immune
PubMed 28216264increased pain
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased pain
- nervous system
- renal
- immune
PubMed 28216264neurodegeneration
Effects
- Activation/Increase/Upregulation: chronic
Studies
- preclinical: neurodegeneration
- nervous system
- renal
- immune
PubMed 28216264decreased pain
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased pain
- nervous system
- renal
- immune
PubMed 28216264
Related records
Trials (415)
- 12-Week Trial Investigating L-carnitine Tartrate, Dihydrocapsiate and Protein Yeast Hydrolysate on Energy Intake and Expenditure in Overweight Adults
- 14-C ADME (Absorption, Disposition, Metabolism and Excretion) Study in Man
- 3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546
- 5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy Volunteers
- A 28 Day Parallel Group Study to Assess the Effects of RDN-929
- A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
- A 6 Months Double Blind Trial to Prevent PONV in Laparoscopic Cholecystectomy
- A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)
- A Bioequivalence Study of Sanchi-Tongshu Capsule (Enteric Coated Pellets)
- A Clinical Study of Gulingji Capsule in the Treatment of Idiopathic Oligospermia, Asthenia, and Teratozoospermia
- A Clinical Study of Treating Influenza With Liugan Shuangjie Heji
- A Clinical Study of Xin'an Medicine in the Treatment of Bi Syndrome
- A Clinical Study of Xin'an Medicine in the Treatment of Knee Osteoarthritis
- A Clinical Study on Qianjin Capsule of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Damp-heat Stasis and Qi Deficiency Syndrome)
- A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects
- A Clinical Trial of CS12192 in Healthy Subjects
- A Clinical Trial of Fecal Microbiota Transplantation in a Population With Obsessive-compulsive Disorder
- A Clinical Trial of KT07 Capsule in the U.S.A
- A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors
- A Clinical Trial of TQH3906 Capsules in Healthy Volunteers
Drugs (4)
- AZD9056 P2X purinoceptor 7 antagonist
- CE-224535 P2X purinoceptor 7 antagonist
- GSK1482160 P2X purinoceptor 7 negative allosteric modulator
- JNJ-54175446 P2X purinoceptor 7 antagonist